• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HSP90β 抑制 STUB1 诱导的 YTHDF2 泛素化以驱动肝癌对索拉非尼的耐药性。

HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.

机构信息

Affiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou, 510095, China.

Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.

出版信息

Adv Sci (Weinh). 2023 Sep;10(27):e2302025. doi: 10.1002/advs.202302025. Epub 2023 Jul 28.

DOI:10.1002/advs.202302025
PMID:37515378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10520652/
Abstract

YTH domain family 2 (YTHDF2) is the first identified N6-methyladenosine (m A) reader that regulates the status of mRNA. It has been reported that overexpressed YTHDF2 promotes carcinogenesis; yet, its role in hepatocellular carcinoma (HCC) is elusive. Herein, it is demonstrated that YTHDF2 is upregulated and can predict poor outcomes in HCC. Decreased ubiquitination levels of YTHDF2 contribute to the upregulation of YTHDF2. Furthermore, heat shock protein 90 beta (HSP90β) and STIP1 homology and U-box-containing protein 1 (STUB1) physically interact with YTHDF2 in the cytoplasm. Mechanically, the large and small middle domain of HSP90β is required for its interaction with STUB1 and YTHDF2. HSP90β inhibits the STUB1-induced degradation of YTHDF2 to elevate the expression of YTHDF2 and to further boost the proliferation and sorafenib resistance of HCC. Moreover, HSP90β and YTHDF2 are upregulated, while STUB1 is downregulated in HCC tissues. The expression of HSP90β is positively correlated with the YTHDF2 protein level, whereas the expression of STUB1 is negatively correlated with the protein levels of YTHDF2 and HSP90β. These findings deepen the understanding of how YTHDF2 is regulated to drive HCC progression and provide potential targets for treating HCC.

摘要

YTH 结构域家族 2(YTHDF2)是第一个被鉴定的 N6-甲基腺苷(m A)阅读器,它可以调节 mRNA 的状态。有报道称,过表达的 YTHDF2 促进了癌症的发生;然而,它在肝细胞癌(HCC)中的作用还不清楚。本研究表明,YTHDF2 上调,并可预测 HCC 的不良预后。YTHDF2 的泛素化水平降低导致其上调。此外,热休克蛋白 90β(HSP90β)和 STIP1 同源和 U -box 包含蛋白 1(STUB1)在细胞质中与 YTHDF2 相互作用。在机制上,HSP90β 的大、小中间结构域是其与 STUB1 和 YTHDF2 相互作用所必需的。HSP90β 抑制 STUB1 诱导的 YTHDF2 降解,从而提高 YTHDF2 的表达水平,进一步促进 HCC 的增殖和索拉非尼耐药性。此外,HCC 组织中 HSP90β 和 YTHDF2 上调,而 STUB1 下调。HSP90β 的表达与 YTHDF2 蛋白水平呈正相关,而 STUB1 的表达与 YTHDF2 和 HSP90β 的蛋白水平呈负相关。这些发现加深了对 YTHDF2 如何被调控以驱动 HCC 进展的理解,并为治疗 HCC 提供了潜在的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/895fd2a01f83/ADVS-10-2302025-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/695c69562ef7/ADVS-10-2302025-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/c6d5e905ac88/ADVS-10-2302025-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/5619c2faba88/ADVS-10-2302025-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/775779ca1de6/ADVS-10-2302025-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/5a8660fe855e/ADVS-10-2302025-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/4dc3fc16f108/ADVS-10-2302025-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/7e255c7c44d6/ADVS-10-2302025-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/895fd2a01f83/ADVS-10-2302025-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/695c69562ef7/ADVS-10-2302025-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/c6d5e905ac88/ADVS-10-2302025-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/5619c2faba88/ADVS-10-2302025-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/775779ca1de6/ADVS-10-2302025-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/5a8660fe855e/ADVS-10-2302025-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/4dc3fc16f108/ADVS-10-2302025-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/7e255c7c44d6/ADVS-10-2302025-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818c/10520652/895fd2a01f83/ADVS-10-2302025-g002.jpg

相似文献

1
HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.HSP90β 抑制 STUB1 诱导的 YTHDF2 泛素化以驱动肝癌对索拉非尼的耐药性。
Adv Sci (Weinh). 2023 Sep;10(27):e2302025. doi: 10.1002/advs.202302025. Epub 2023 Jul 28.
2
MicroRNA-145 Modulates -Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the -Methyladenosine Binding YTH Domain Family 2 Protein.微小RNA-145通过靶向N6-甲基腺苷结合YTH结构域家族2蛋白的3'-非翻译mRNA区域来调节N6-甲基腺苷水平。
J Biol Chem. 2017 Mar 3;292(9):3614-3623. doi: 10.1074/jbc.M116.749689. Epub 2017 Jan 19.
3
TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.TAK1 是肝细胞癌的一个新靶点,促进索拉非尼耐药。
Cell Mol Gastroenterol Hepatol. 2021;12(3):1121-1143. doi: 10.1016/j.jcmgh.2021.04.016. Epub 2021 May 5.
4
O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N-methyladenosine-dependent manner.O-GlcNAc 修饰的 YTHDF2 通过 N6-甲基腺苷依赖性方式促进 HBV 相关肝细胞癌进展。
Signal Transduct Target Ther. 2023 Feb 10;8(1):63. doi: 10.1038/s41392-023-01316-8.
5
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.YTHDF2 通过抑制 ETV5/PD-L1/VEGFA 轴抑制免疫逃逸和血管生成,是 HCC 的治疗靶点。
Adv Sci (Weinh). 2024 Apr;11(13):e2307242. doi: 10.1002/advs.202307242. Epub 2024 Jan 21.
6
Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.长链非编码 RNA 1273 通过调控甲基转移酶 3 赋予肝癌索拉非尼耐药性。
Bioengineered. 2022 Feb;13(2):3108-3121. doi: 10.1080/21655979.2022.2025701.
7
FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.FBXL6 通过泛素化和稳定 HSP90AA1 来调控 c-MYC 促进肝细胞癌。
Cell Commun Signal. 2020 Jun 23;18(1):100. doi: 10.1186/s12964-020-00604-y.
8
Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma.Hsp90β 通过上皮-间充质转化促进肝癌侵袭性血管生成拟态。
Oncogene. 2019 Jan;38(2):228-243. doi: 10.1038/s41388-018-0428-4. Epub 2018 Aug 7.
9
MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24.miR-21-5p 通过调控 USP24 对 SIRT7 的泛素化作用促进索拉非尼耐药和肝癌进展。
Life Sci. 2023 Jul 15;325:121773. doi: 10.1016/j.lfs.2023.121773. Epub 2023 May 13.
10
LINC00707 impairs the Natural Killer cell antitumour activity in hepatocellular carcinoma through decreasing YTHDF2 stability.LINC00707 通过降低 YTHDF2 的稳定性来损害肝癌中的自然杀伤细胞抗肿瘤活性。
J Cell Mol Med. 2024 Mar;28(5):e18106. doi: 10.1111/jcmm.18106. Epub 2024 Jan 18.

引用本文的文献

1
The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease.STUB1-TPIT轴调节库欣病中促肾上腺皮质激素的分泌。
J Transl Med. 2025 Aug 26;23(1):961. doi: 10.1186/s12967-025-06960-y.
2
Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer.血浆HSP90α升高作为表皮生长因子受体(EGFR)突变的非小细胞肺癌的预后标志物
Oncol Lett. 2025 Jul 22;30(4):457. doi: 10.3892/ol.2025.15203. eCollection 2025 Oct.
3
Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma.

本文引用的文献

1
O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N-methyladenosine-dependent manner.O-GlcNAc 修饰的 YTHDF2 通过 N6-甲基腺苷依赖性方式促进 HBV 相关肝细胞癌进展。
Signal Transduct Target Ther. 2023 Feb 10;8(1):63. doi: 10.1038/s41392-023-01316-8.
2
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.SNS-023 通过诱导致癌驱动基因 SIX1 和 RPS16 的降解,增强肝癌对索拉非尼的敏感性。
Acta Pharmacol Sin. 2023 Apr;44(4):853-864. doi: 10.1038/s41401-022-01003-4. Epub 2022 Oct 19.
3
A SIX1 degradation inducer blocks excessive proliferation of prostate cancer.
沉默NEDD4L可有效抑制肝癌的恶性行为。
J Hepatocell Carcinoma. 2025 Jul 10;12:1369-1391. doi: 10.2147/JHC.S511466. eCollection 2025.
4
Dihydrotanshinone I Targets PGAM1 to Induce SYVN1-Mediated Ubiquitination and Suppress Glycolysis in Hepatocellular Carcinoma.二氢丹参酮 I 通过靶向磷酸甘油酸变位酶 1 诱导 SYVN1 介导的泛素化并抑制肝癌细胞的糖酵解
Phytother Res. 2025 Aug;39(8):3762-3783. doi: 10.1002/ptr.70017. Epub 2025 Jul 10.
5
CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancer.环状ERC1通过抑制细胞焦亡和重塑胰腺癌的细胞外基质促进化疗耐药。
Mol Cancer. 2025 Jul 2;24(1):185. doi: 10.1186/s12943-025-02385-9.
6
The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression.去泛素化酶USP7可稳定HER2表达并促进乳腺癌进展。
Neoplasia. 2025 Aug;66:101192. doi: 10.1016/j.neo.2025.101192. Epub 2025 Jun 4.
7
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation.FAM64A通过抑制TWIST1的泛素化和降解促进卵巢癌的增殖和转移。
Endocr Relat Cancer. 2025 Jun 16;32(6). doi: 10.1530/ERC-24-0048. Print 2025 Jun 1.
8
Machine learning-based multimodal radiomics and transcriptomics models for predicting radiotherapy sensitivity and prognosis in esophageal cancer.基于机器学习的多模态放射组学和转录组学模型用于预测食管癌的放疗敏感性和预后。
J Biol Chem. 2025 May 15;301(7):110242. doi: 10.1016/j.jbc.2025.110242.
9
Doublecortin-like kinase 1, regulated by STIP1 homology and U-box containing protein 1 or Sp1 transcription factor, affects the malignant behaviors and drug sensitivity in adriamycin-resistant breast cancer cells.由含STIP1同源性和U盒结构域蛋白1或Sp1转录因子调控的双皮质素样激酶1影响耐阿霉素乳腺癌细胞的恶性行为和药物敏感性。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 21. doi: 10.1007/s00210-025-04159-y.
10
SOX11 exacerbates ferroptosis to reduce lenvatinib resistance in liver cancer cells by promoting ubiquitination degradation of SREBF1 through upregulating UBE3A.SOX11通过上调UBE3A促进SREBF1的泛素化降解,从而加剧铁死亡以降低肝癌细胞对乐伐替尼的耐药性。
Mol Cell Biochem. 2025 Mar 1. doi: 10.1007/s11010-025-05218-x.
一种 SIX1 降解诱导剂可阻断前列腺癌细胞的过度增殖。
Int J Biol Sci. 2022 Mar 14;18(6):2439-2451. doi: 10.7150/ijbs.67873. eCollection 2022.
4
mA binding protein YTHDF2 in cancer.癌症中的mA结合蛋白YTHDF2
Exp Hematol Oncol. 2022 Apr 5;11(1):21. doi: 10.1186/s40164-022-00269-y.
5
Quality control of protein complex assembly by the ubiquitin-proteasome system.泛素-蛋白酶体系统对蛋白质复合物组装的质量控制。
Trends Cell Biol. 2022 Aug;32(8):696-706. doi: 10.1016/j.tcb.2022.02.005. Epub 2022 Mar 14.
6
METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an mA-YTHDF2-dependent manner.METTL3通过以mA - YTHDF2依赖的方式调节IFIT2的表达来促进肝内胆管癌的进展。
Oncogene. 2022 Mar;41(11):1622-1633. doi: 10.1038/s41388-022-02185-1. Epub 2022 Jan 29.
7
YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.YTHDF2通过STAT5A/MAP2K2/p-ERK轴促进多发性骨髓瘤细胞增殖。
Oncogene. 2022 Mar;41(10):1482-1491. doi: 10.1038/s41388-022-02191-3. Epub 2022 Jan 24.
8
The role of m6A RNA methylation in cancer metabolism.m6A RNA 甲基化在癌症代谢中的作用。
Mol Cancer. 2022 Jan 12;21(1):14. doi: 10.1186/s12943-022-01500-4.
9
Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.选择性降解 AR-V7 以克服前列腺癌的去势抵抗。
Cell Death Dis. 2021 Sep 21;12(10):857. doi: 10.1038/s41419-021-04162-0.
10
USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells.USP1 依赖性 RPS16 蛋白稳定性驱动人肝细胞癌细胞的生长和转移。
J Exp Clin Cancer Res. 2021 Jun 21;40(1):201. doi: 10.1186/s13046-021-02008-3.